A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer
Clinical trial NCT05145218 · UNKNOWN
Trial details
- NCT number
- NCT05145218
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-28
- Primary completion
- 2024-10-01
- Enrollment
- 405
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.